Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karen Rex

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Plos One|July 18, 2013
Sphingosine kinase activity is not required for tumor cell viabilityKaren Rex, Shawn Jeffries, Matthew L Brown, et al.
Journal of Medicinal Chemistry|January 27, 2016
Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor ActivityAlessandro A Boezio, Katrina W Copeland, Karen Rex, et al.
Bioorganic & Medicinal Chemistry Letters|July 13, 2013
Structure guided design of a series of sphingosine kinase (SphK) inhibitorsDarin J Gustin, Yihong Li, Matthew L Brown, et al.
Journal of Medicinal Chemistry|September 4, 2008
Design, synthesis, and biological evaluation of potent c-Met inhibitorsNoel D D'Angelo, Steven F Bellon, Shon K Booker, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2009
Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitorsAlessandro A Boezio, Loren Berry, Brian K Albrecht, et al.
Nature Communications|May 2, 2025
LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancersChendi Li, Mohammed Usman Syed, Anahita Nimbalkar, et al.
Journal of Medicinal Chemistry|April 23, 2008
Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinaseBrian K Albrecht, Jean-Christophe Harmange, David Bauer, et al.
ACS Medicinal Chemistry Letters|April 21, 2016
Discovery and Optimization of Macrocyclic Quinoxaline-pyrrolo-dihydropiperidinones as Potent Pim-1/2 Kinase InhibitorsVictor J Cee, Frank Chavez, Bradley Herberich, et al.
Journal of Medicinal Chemistry|June 11, 2016
Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase InhibitorsLiping H Pettus, Kristin L Andrews, Shon K Booker, et al.
Molecular Cancer Therapeutics|October 13, 2010
Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibodyAngela Coxon, James Bready, Hosung Min, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Plos One|July 18, 2013
Sphingosine kinase activity is not required for tumor cell viabilityKaren Rex, Shawn Jeffries, Matthew L Brown, et al.
Journal of Medicinal Chemistry|January 27, 2016
Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor ActivityAlessandro A Boezio, Katrina W Copeland, Karen Rex, et al.
Bioorganic & Medicinal Chemistry Letters|July 13, 2013
Structure guided design of a series of sphingosine kinase (SphK) inhibitorsDarin J Gustin, Yihong Li, Matthew L Brown, et al.
Journal of Medicinal Chemistry|September 4, 2008
Design, synthesis, and biological evaluation of potent c-Met inhibitorsNoel D D'Angelo, Steven F Bellon, Shon K Booker, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2009
Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitorsAlessandro A Boezio, Loren Berry, Brian K Albrecht, et al.
Nature Communications|May 2, 2025
LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancersChendi Li, Mohammed Usman Syed, Anahita Nimbalkar, et al.
Journal of Medicinal Chemistry|April 23, 2008
Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinaseBrian K Albrecht, Jean-Christophe Harmange, David Bauer, et al.
ACS Medicinal Chemistry Letters|April 21, 2016
Discovery and Optimization of Macrocyclic Quinoxaline-pyrrolo-dihydropiperidinones as Potent Pim-1/2 Kinase InhibitorsVictor J Cee, Frank Chavez, Bradley Herberich, et al.
Journal of Medicinal Chemistry|June 11, 2016
Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase InhibitorsLiping H Pettus, Kristin L Andrews, Shon K Booker, et al.
Molecular Cancer Therapeutics|October 13, 2010
Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibodyAngela Coxon, James Bready, Hosung Min, et al.
Pageof 4